BRAFi/MEKi second-line therapy effective in metastatic melanoma

A combination of BRAF and MEK inhibitors (BRAFi/MEKi) is an effective second-line therapy in patients with advanced and metastatic melanoma, according to a study.

Patients included in this study were treated with first-line immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors, followed by second-line treatment with ≥1 cycle of BRAFi/MEKi therapy.

A total of 97 patients were included. The median overall survival was 19.9 months after the initiation of first-line treatment and 12.8 months since the initiation of treatment with BRAFi/MEKi. All BRAFi/MRKi combinations had similar efficacy. The median progression free survival was 7.5 months since the start of any BRAFi/MEKi treatment.

Reference
Rogala P, Czarnecka AM, Cybulska-Stopa B, et al. Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients-Real-World Evidence. J Clin Med. 2022;11(8):2239. doi: 10.3390/jcm11082239. PMID: 35456332; PMCID: PMC9032972.